Investigational New Drug
-
Glenmark receives US FDA nod for GRC 54276 to treat advanced solid tumours and lymphomas
GRC 54276 is an orally available, small-molecule hematopoietic progenitor kinase 1 (HPK1) inhibitor Glenmark Specialty, the subsidiary of Glenmark Pharmaceuticals,…
Read More »